Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
John R BrightRosina T LisAnson T KuNicholas T TerriginoNichelle C WhitlockShana Y TrostelNicole V CarrabbaStephanie A HarmonIsmail Baris TurkbeyScott WilkinsonAdam G SowalskyPublished in: The Journal of urology (2022)
We propose that anti-PSMA immunostaining be a standardized marker for identifying residual cancer in the setting of iADT.